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1. Introduction 
Successful kidney transplantation improves the quality of life and increases survival when 
compared with long-term dialysis. Renal transplantation is now a well established and the 
preferred treatment for most patients with end-stage renal disease (ESRD). In recent years, 
the short-term effects of kidney transplantation have been greatly achieved due to the 
improvement in immunosuppression medicines, better genotyping technology and 
monitoring methods. However, the long-term outcome of kidney transplantation has not 
been improved for long period. Among the various influencing factors, antibody-mediated 
kidney allograft rejection is now widely recognized as a major problem which decreases the 
long-term outcome. How many kinds of antibodies involved in the antibody-mediated 
rejection (AMR)? How do these antibodies produce? How do these antibodies injure the 
transplantated kidney function? How to eliminate these antibodies? How about the clinical 
effects when the new agents were applied? All these questions are being gradually and 
deeply studied. 
2. Anti-HLA and MHC-class I related chain A antibody 
At present, anti-HLA antibody (Lefaucheur et al., 2010) and anti-MHC-class I related chain 
Antibody (Zou et al., 2009) are the main cytotoxic antibodies, resulting in kidney allograft 
rejection and long-term kidney allograft survival. 
2.1 Anti-HLA antibody 
HLA (the human leukocyte antigen system) is the name of the major histocompatibilty 
complex (MHC) in humans. MHC molecules are divided into 2 main classes: HLA class I 
antigens (HLA-A, -B, and –C), presented on the surface of all nucleated cells and platelets; 
and HLA class II antigens (HLA-DR, -DQ, -DP, -DM and –DO), expressed on professional 
antigen-presenting cells, but also on the surface of vascular endothelial cells and renal 
tubular epithelial cells. There lie high polymorphism degree of the HLA system (more than 
1600 alleles), so the individuals do not present identical sets of HLA antigens. After solid 
organ transplantation, HLA polymorphism confers immunological identity to the recipients, 
thus, the immune system can distinguish between self and non-self, and non-self may 
represent targets for the immune system. T cellular-mediated rejection (TCMR) and/or 
AMR will be initiated. As for AMR, donor specific anti-HLA antigens -I and -II 
alloantibodies would be produced. 
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The presence of alloantibodies against donor HLA-I and HLA-II antigens has been 
associated with hyperacute and accelarated graft rejection. Since HLA typing is strictly 
requested before renal transplantation (RTx), whatever cadaveric RTx, or living related or 
non-related RTx, the incidence of hyperacute and accelarated graft rejection have been 
greatly decreased.  
However, some evidences suggest that donor specific antibody (DSA) is common in RTx 
recipients after 1 year of operation, which may be explained by the HLA polymorphism.  
2.2 Anti-MHC-class I related chain A antibody (MICA) 
MHC-class I related chain (MIC) has been reported to be an important polymorphic 
alloantigen system, consisting of MICA and MICB, and distributing on the peripheral blood 
lymphocytes, tissue endotheliocytes, and umbilical endotheliocytes, which also play a role 
in renal allograft rejection. Specific anti-MICA antibody can be found in sera of transplanted 
patients with allograft rejection (Zou et al, 2007). And the statistical analysis indicated that, 
anti-MICA antibodies were associated with the failure of a renal graft, regardless of good 
HLA typying (0 or 1 HLA mis matched) and PRA =0.  
One report showed that, despite negative pretransplantation T- and B- lymphocyte flow 
cytometric crossmatches and blood group identity, two cases of hyperacute humoral 
rejection of living related kidney grafts happened (Grandtnerova et al, 2008). 
Retrospectively, antiendothelial IgG antibodies were detected on a panel of umbilical cord 
cells in the first case, and IgM antibodies against donor endothelial precursor cells were 
detected using a new endotheilal cell crossmatch kit in the second case. Standard crossmatch 
methods using donor lymphocytes failed to detect these pathogenic antibodies and did not 
predict the danger of hyperacute rejection. 
Now, MIC typying is still not carried out in clinic. Were the antiendothelial IgG and IgM 
antibody all belonging to anti-MICA antibody? This question may be worth investigating. 
2.3 Subtypes of alloantibodies 
IgM-alloantibody and IgG-alloantibody are all common in the peripheral blood and 
intragraft of recipients, and they are all involved in kidney allograft rejection. 
IgM antibodies against donor HLA antigens can be found before transplantation and also 
produced both early and late in the post-transplant course. IgM antibodies against donor 
HLA appear to be associated with decreased survival of kidney and heart allografts.  
IgG1/IgG3 and IgM can specially bind to alloantigens, activate complement system, and 
play their immunological action. While IgG2 only weakly activate complement system, and 
IgG4 does not activate complement system. IgG1/IgG3 and IgM probably participate in 
AMR by this pathway. 
This viewpoint is concordant to the observed evidence. For example, three cases of 
successful living donor kidney transplantation, showed strongly positive B lymphocyte flow 
cytometry owing to highly reactive DSA directed to HLA Ċ antigens. IgG solid-phase 
subtypes analysis suggested that, more than 50% of these antibodies were represented by 
non-complement binding IgG2/IgG4 subtypes (Lobashevsky et al., 2010). 
Now, new technologies are quickly developed. Some new methods based on solid phase 
multiplex platforms, such as ELISA, flow cytometry and luminex, have been applied in 
clinic. These methods can detect binding of serum antibodies to specific antigens 
independently of complement activation. And, using additional anti-IgM/IgG antibodies, 
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these new technologies can distinguish between IgM and IgG anti-HLA antibodies. 
Additionally, it can discriminate between HLA class I and class II antibodies, and more, 
single antigen methods allow identification of a unique HLA specificity. 
With the help of development in detection technology, clinician can obtain more precise 
information and make rational decision.  
2.4 Potential mechanism 
After these antibodies are produced, they will attack their targets represented by the graft 
endothelial cells, complement system would be activated, coagulation cascade happened 
and other inflammation factors would be produced. This procedure may be the most 
classical procedure of AMR. 
The microcirculation characteristic of microcirculation changes of AMR include of:  
(1) Microcirculation inflammation (glomerulitis (g), peritubular capillaritis (ptc))(Einecke et 
al., 2009); (2) Microcirculation deterioration (transplant glomerulopathy (cg), medangial 
matrix increase (mm)); (3) Peritubular capillary basement membrane multilayering (ptcm-
score) ; (4) Diffuse C4d positivity.  
A key element in the pathology of AMR is capillaritis, which is associated with glomerulitis 
and anti-HLA antibodies. Over time it seems likely that capillaritis will induce peritubular 
capillary basement membrane multilayering as a time dependent feature of late AMR. 
3. Antibody-producing cells 
3.1 Characterization of intra-graft B cells 
During renal allograft rejection, cluster-forming CD20+ B cells in the rejected graft are likely 
derived from the recipient and composed of mature B cells. These cells are activated 
(CD79a+), some of them contain memory B cells (CD27+) and do not correlate with intra-
graft C4d deposition or with donor-specific antibody detection.  
Furthermore, several non-cluster forming CD20- B-lineage CD38+ plasmablasts and plasma 
cells infiltrate in the rejected grafts and these cells strongly correlated with circulating 
donor-specific antibody, and to a lesser extent with intra-graft C4d.  
Both CD20+ B cells and CD38+ cells correlated with poor response of the rejection to steroids. 
Reduced graft survival is associated with the presence of CD20 cells in the graft. 
And, a specific subset of early lineage B cells appears to be antigen-presenting cells and which 
may support a steroid-resistant T-cell-mediated cellular rejection when these cells present in 
the rejected graft. Late lineage interstitial plasmablasts and plasma cells may also support 
AMR. These studies suggest that detailed analysis of interstitial cellular infiltrates may allow 
better use of B-cell lineage specific treatments to improve graft outcomes.  
3.2 Plasma cells and memory B cells 
Now the exact cellular mechanisms responsible for AMR are still not known. It seems likely 
that both pre-existing plasma cells and the conversion of memory B cells to new plasma cells 
play a role in the increased DSA production (Stegall et al., 2010).  
There indeed normally exists very little amount of long-lived plasma cells, but they may not 
be able to produce enough pathological alloantibodies to injury the kidney allograft. Plasma 
cells, DSA and C4d are associated with each other in renal transplants developing chronic 
rejection by sequential graft biopsies detection. Bone-marrow-derived long-lived plasma 
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cells appear to be a major source of donor-specific alloantibody in sensitized renal 
transplant recipients. Memory B cells appear to be important in early acute AMR, but few 
basic have been performed. 
3.3 Potential survival factor: BAFF 
Some factors may survive the plasma cells or enhance the production of pathological 
alloantibodies. B cell activating factor belonging to TNF superfamily (BAFF) may be one of 
the most potential survival factors. BAFF is also termed Blys, TALL-1, zTNF4, THANK and 
TNFSF13b, is a nomotrimer, member of the TNF superfamilies, expressed on the cell surface 
or cleaved and secreted. BAFF specifically binds to BAFF receptor (BAFF-R, also known as 
BR3 (Thompson, et al., 2001)), and BAFF can also bind to other two receptors, 
transmembrane activator and calcium-modulator and cyclophilin ligand interactor (TACI) 
and B-cell maturation antigen (BCMA), shared with another TNF ligand, a proliferation-
inducing ligand (APRIL) (Day, et al., 2005). 
BAFF is expressed by monocyte-derived cells, such as monocytes, macrophages, dendritic 
cells, and activated T lymphocytes, which plays an important role in immune response 
(Mackay, F. and Schneider, P. 2009). The discovery of BAFF has shed new light on the 
importance of finely tuned B cell survival for B cell tolerance during B cell maturation and 
activation. Excessive production of BAFF is associated with the development of 
autoimmune diseases, because transgenic (Tg) mice that overproduce BAFF develop severe 
autoimmune disorders resemble systemic lupus erythematosus (SLE) and Sjogren’s 
syndrome (SS) in humans, possibly as a result of improper B cell survival, predominantly 
affecting the maturing splenic transitional type 2 (T2) and the marginal zone (MZ) B cell 
populations. BAFF-induced autoimmunity in BAFF Tg mice appears to be highly dependent 
on B cells and possibly the production of autoantibodies. High levels of BAFF have been 
found in the blood of patients with autoimmune diseases, particularly SLE and SS. And 
BAFF is also found on T lymphocytes infiltrating labial salivary glands from patients with SS. 
3.3.1 BAFF and rituximab 
Rituximab can specially delete CD20+ B lymphocytes, gradually applied to induce 
immunosuppression state at present. The impact of rituximab therapy on tertiary lymphoid 
organs associate with chronic active antibody-mediated rejection, a prototypic humoral 
chronic inflammatory condition. In certain patients, inflammatory microenvironment 
provides BAFF-dependent paracrine survival signal to B-cells in tertiary lymphoid organs, 
allowing them to escape rituximab-induced apoptosis, thereby thwarting therapeutic 
efficiency (Thaunat et al. 2008). 
3.3.2 BAFF and alemtuzumab 
BAFF is increased in renal transplant patients following treatment with alemtuzumab 
(Bloom et al. 2009). Alemtuzumab is an anti-CD52 monoclonal antibody that can deplete T 
and B cells and is used as induction therapy for renal transplant recipients. However 
without long-term calcineurin inhibitor (CNI) therapy, alemtuzumab-treated patients have a 
prospensity to develop alloantibody and may undergo AMR.  
These data suggest associations between BAFF signal and AMR in alemtuzumab-treated 
patients.  
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3.3.3 BAFF and renal transplantation 
In view of special bioactivity of BAFF, experiments have been carried through to explore the 
expression characteristic of BAFF and its potential bioactivity in renal allograft rejection, and 
some significant results were obtained.  
3.3.3.1 BAFF expression and serum PRA 
The FACS (Fluorescence Activated Cell Sorter) results indicated that, cell surface BAFF was 
abnormally highly expressed on peripheral T lymphocytes of some kidney transplant 
recipients, especially in those recipients for more than 5 years (Fig.1).  
 
 
Fig. 1. BAFF expression on CD3+ T lymphocytes in RTx recipients after 5 yrs’ operation 
The real-time PCR (Polymerase Chain Reaction) results showed that BAFF mRNA levels 
gradually increased along with the prolonged transplantation time, and BAFF mRNA levels 
were consistent with BAFF protein levels in different groups (Fig.2). 
 
 
Fig. 2. BAFF mRNA levels in peripheral blood monocytes of RTx recipients after operation 
with different periods (<1 yr, 1-4 yr and ≥5 yr) 
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Healthy volunteers and uremia dialysis patients as controls 
To investigate the correlation of transplanted renal function and BAFF expression, 
transplanted renal function was stratified and these data were statistically analyzed. In 
abnormal renal function group, BAFF was abnormally highly expressed on peripheral T 
lymphocytes, and the expression level was about as high as that in ≥ 5 years group. And 
there was statistically significant association between anti-HLA I & II antibodies level and 
BAFF expression level (Tab.1).  
 
 anti-HLA ĉ&Ċ antibodies 
CD257 
Person Correlation .587** 
Sig (2-tailed) .008 
Table 1. The correlation analysis of BAFF expression and serum PRA (panel reactive 
antibody) 
The results indicated that BAFF expression was correlated with gradually decreasing 
transplant renal function, and BAFF may be involved in immune regulating network of 
kidney transplantation, which was the first report about BAFF and kidney transplantation.  
3.3.3.2 BAFF and its receptors in the allograft rejection tissues 
To further investigate the role of BAFF in AMR in renal transplantation, the correlation of 
BAFF and C4d deposition in excised transplanted kidney and protocol biopsies were 
investigated. The results showed that, BAFF could not only be found in renal allograft 
tissues, including AR and IF/TA (Interstitial Fibrosis/Tubular Atrophy) tissues, but also 
was highly expressed in these allograft sections, compared to protocol biopsy sections. 
BAFF can regulate the development of transitional B lymphocytes and survival of 
plasmacytoid lymphocytes, which implies that the BAFF signal may participate in AMR. To 
test this presumption, C4d and IgG were also detected in these allograft sections by 
immunohistochemistry. The results showed that BAFF expression significantly correlated 
with C4d deposition. The intensity and percentage score of BAFF were similar to those of 
C4d. BAFF mainly distributed in the perinephric tubular epithelial cell cytoplasm and 
cytomembrane, similar to the distribution of C4d. There was IgG deposition in BAFF high-
expression sections, but its intensity and percentage score were much weaker than BAFF. 
IgG deposition was also mainly distributed in the perinephric tubular epithelial cell 
cytoplasm and cytomembrane. 
The patients’ clinical materials were shown in Tab.2. And the representative examples of 
immunohistochemical (IHC) staining of BAFF and C4d in renal allograft rejection tissues 
were listed in Fig. 3. 
 
groups 
gender 
Male/ 
female 
Age (year) 
(means±SD) 
PRA(%) 
HLA-DR non-
matched level 
POD(day, 
means±SD) 
Graft 
failure 
AR(n=10) 6/4 39±10 (19~58) 17±4.1 0.8±0.6 (0~2) 9±8 
UAC(n=9) 4/5 42±8 (32~56) 5±4.2 0.7±0.7 (0~2) 1875±784 
Graft 
normal 
Protocol 
renal biopies 
(n=10) 
7/3 37±5 (26~48) 7.4±3.5 0.7±0.7 (0~2) 17±4 
Table 2. All the accepted patients’ clinical materials 
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Fig. 3. Representative examples of immunohistochemical staining of BAFF and C4d in renal 
allograft rejection (original mannification 200X).Positive staining was observed as a dark brown 
color. Renal allograft rejection tissues showed strong expression of C4d (A) and BAFF (B). 
We performed further study by IHC to investigate the receptors of BAFF involved in the 
renal allograft rejection. The TACI, BCMA and BAFF-R (BAFF receptor, BR3) were all 
detected. And the APRIL, much high homogenicity with BAFF, was also done. Meanwhile, 
the plasma cell marker CD138 was also investigated.  
The obtained data showed that, high immunogenicity of BAFF, APRIL and their receptors, 
TACI, BCMA and BAFF-R, and CD138 can be found in renal allograft rejection tissues 
(including of acute and chronic rejection) (Fig.4), while these molecules all have low 
immunogenicity in other etiological tissue (excluding of acute and chronic rejection).  
All data were analyzed according to C4d expression. In C4d negative group, BAFF, BAFF-R, 
BCMA and CD138 were all low immunogenicity, while APRIL and TACI have high 
immunogenicity. In C4d positive group, BAFF, BAFF-R, BCMA, APRIL, TACI and CD138 
were all high immunogenicity. The statistical analysis suggested that, the expression of 
BAFF, BAFF-R, BCMA and CD138 significantly correlated with C4d deposition (Fig.5). 
These results suggest that BAFF signal may participate in AMR, and APRIL signal may 
simultaneously participate in cell-mediated and antibody-mediated rejection. 
4. Diagnosis of AMR 
4.1 Diagnosis of acute AMR  
AMR may occur early or late, may be acute or chronic and is associated with poor renal 
allograft function and survival. According to the speed of rejection, three AMR conditions are 
now recognized: hyperacute, subacute and chronic AMR. 
The following items are required in diagnosis of acute AMR:  
1. Histopathological evidence of either acute tubular injury (with no other identifiable 
cause for it), glomerulitis, endothelitis or capillaritis with neutrophil or mononuclear 
cell infiltratem capillary thrombosis; 
2. Serologica evidence of circulating antibodies; 
3. Diffuse C4d positivity in peritubular capillaries (PTC). 
These diagnosis criteria are based on Banff 2005 guidelines, in which, C4d deposition in the 
peritubular capilary (PTC) is considered as the mark of AMR.  
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(A）CD256 (×400)                                       (B) TACI (×400) 
   
(C) BAFF-R (×400)                          (D) BCMA (×400) 
  
(E) CD138 (×400)                                   (F) IgG isotype (×400) 
Fig. 4. The representative IHC staining results of APRIL, TACI, BAFF-R, BCMA and CD138 
were listed (×400). The APRIL, BAFF-R,BCMA and CD138 signal were developed with 3,3’-
diaminobenzidine tetrahydrochloride (DAB), the dark brown particles were the positive 
signal. And TACI signal was developed with 3-amino-9-ethycarbozole (AEC), the red 
particle was the positive signal. (F): the IgG isotype of the used antibodies.  
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Fig. 5. All data was analyzed according to C4d immunoreactivity, C4d(-) represented C4d 
negative group and C4d(+) represented C4d positive group. There were significant 
difference of the expression rate of BAFF, BAFF-R and BCMA between C4d(-) group and 
C4d(+) group. P<0.05 was considered as statistical significance. * P<0.05. 
4.2 Suspicious for AMR 
However, C4d staining is found to be not completely useful in diagnosis of AMR with the 
advancement of knowledge about AMR. For example, C4d staining in post-reperfusion 
renal biopsy is not useful for the early detection of AMR when CDC crossmatching is 
negative (David-Neto et al., 2010). In ABO-incompatible transplant cases, AMR is difficult to 
be diagnosed by C4d analysis.  
Banff 09 meeting discussed several aspects of solid organ transplants with a special focus on 
antibody mediated graft injury, and revised the diagnosis indexes.  
Because C4d may not be sensitive in the diagnosis of AMR: many cases of transplant 
glomerulopathy with anti-HLA are C4d negative (Sis et al., 2009). Therefore, the recent 
update of the Banff classification introduced the diagnostic category “suspicious for AMR” 
if C4d (in the presence of antibody) or alloantibody (in the presence of C4d) cannot be 
demonstrated but morphologic evidence of antibody-mediated tissue injury is present. 
Moreover, in microarray studies, expression of endothelial transcripts was increased in 
biopsies with DSA and associated with graft loss even in C4d negative biopsies. 
4.3 Remained questions  
The risk for graft loss is not captured well by the current Banff diagnoses because many cases 
with AMR features (anti-HLA and microcirculation changes) were C4d negative and thus 
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given other diagnosis. However, when AMR is redefined as the presence of HLA antibody 
and microcirculation changes, regardless of C4d status, it is the most frequent phenotype 
associated with subsequent graft loss. In contrast, nonspecific scarring (IFTA), calcineurin 
inhibitor toxicity and TCMR are rare diagnosis in grafts that subsequently failured. Thus, 
antibody-mediated microcirculation injury accounts for the majority of kidneys presenting 
with indications for biopsy and subsequently failing, but many cases are C4d negative. 
Subclinical AMR seems to be complicated by a substantial proportion of positive-crossmatch 
transplantations even in the absence of allograft dysfunction, and may result in chronic 
histological abnormalities and shorten allograft function (Loupy et al., 2009).  
So, although much advancement have been obtained in diagnosis, there is still absent of 
specific marker to aid the diagnosis and therapeutic of AMR.   
5. Therapeutic strategies of AMR 
Once AMR happen, it requires intensive therapy, but no standard treatment has been 
established now. To eliminate the alloantibodies and antibody-producing cells are the main 
strategy of AMR treatment. 
5.1 Therapeutic strategies of acute AMR 
Now, several strategies are being routinely applied, such as plasmapheresis, high-dose 
intravenous immunoglobulin (IVIG) and plasmapheresis (PP) with low-dose IVIG. Some 
new interventions have been applied in clinic, such as the use of rituximab (anti-CD20 
chimeric antibody)(Rodriguez et al. 2010; Takagi et al., 2010), bortezomib (a proteasome 
inhibitor-mediated plasma cell depletion)(Raghavan et al. 2010; Walsh et al., 2010), and 
eculizumab (recombinant human C5-inhibitor)(Lonze et al., 2010; Tillou et al.,2010), for 
preventing acute AMR. These methods are promising therapeutic avenues currently under 
investigation. 
IVIG has many ideal advantages as a therapy for AMR.  
1. It can down regulate B-cell activation and antibody production.  
2. It can induce anti-inflammatory cytokines and contain blocking antiidiotyic antibodies 
to anti-HLA antibodies;  
3. IVIG has the unique ability to block complement-mediated injury through inhibition of 
C3 activation.  
Rituximab (anti-CD20 chimeric antibody) can deplete B cells and interfere with antigen-
presenting cell (APC) activity of B cells subsequently decreasing T-cell activation, 
Bortezomib is one kind of proteasome inhibitors. The preliminary results indicate that 
bortezomib therapy provides effective reduction in DSA levels with long-term suppression 
in transplant recipients.  
Bortezomib therapy’s advantages: 
1. It provides effective treatment of AMR and TCR with minimal toxicity. 
2. It provides sustained reduction in iDSA and non-iDSA levels.  
While, other center reported that, Bortezomib treatment did not significantly decrease DSA 
within the 150-day posttreatment period in any patient; lack of efficacy on long-lived plasma 
cells. So, one cycle of bortezomib alone does not decrease DSA levels in sensitized kidney 
transplant recipients in the time period studied. These results underscore the need to 
evaluate this new desensitization agent properly in prospective, randomized and well-
controlled studies (Sberro-Soussan et al., 2010). 
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5.2 Therapeutic strategies of subacute and chronic AMR 
Now, there seems to have not any good methods to treatment the subacute and chronic 
AMR. Although subacute and chronic AMR are not immediately result in the graft loss, they 
cause chronic histological injury and shorten allograft function. Many evidences have 
suggested that AMR is the important factor influencing the long-term of kidney allograft. 
Thus, great efforts are still needed to resolve this problem. 
6. Conclusion 
In summary, recent advances in the diagnosis and treatment of AMR has allowed for 
significant improvements in the outcome of a condition usually associated with rapid graft 
failure. However, much work needs to be done to better understand the immunologic 
processes leading to AMR and how current therapies can be best used to effectively prevent 
and treat it. 
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